Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganshuang granules combined with tenofovir for CHB and NAFLD
NCT05523648Phase 1Completed
- Sponsor
- Leshan Traditional Chinese Medicine Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ganshuang Keli in Chronic Hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Leshan Traditional Chinese Medicine Hospital. Primary endpoints: Alanine Aminotransferase at 24 weeks, Aspartate Aminotransferase at 24 weeks and 4 more. Started Jan 2020; status: completed.
02
Drugs
Ganshuang Keli
03
Conditions
Chronic Hepatitis B (CHB)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05523648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523648.